Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Used in the treatment of hepatitis C, usually in combination with other antivirals.
Since the last update we have not found published data on its excretion in breast milk.
Its pharmacokinetic data (slightly elevated molecular weight and very high percentage of plasma protein binding) make it very unlikely that significant amounts will pass into milk, so that although there is disagreement (Thompson 2016, Spera 2016), other experts believe that treatment with Paritaprevir, on its own or in combination with Ombitasvir and ritonavir or with Ombitasvir, Ritonavir and Desabuvir is not contraindicated during breastfeeding (LactMed 2016).
See below the information of these related products: